Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Pfizer continues to dominate the neurology drug market with 37% market share. The report entitled Neurology Pipeline Analysis: Top Companies Maintain Position Through 2007 notes that Pfizer has a drug in each neurology category discussed-Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy.

"Although Pfizer will remain the leader in the neurological drug market in 2007, Johnson & Johnson (J&J) and Novartis will also become key players in this therapeutic area, capturing 12% and 11% of the market, respectively, said Heather Martin, analyst at Decision Resources. "J&J's products--topiramate (Topamax) for epilepsy and galantamine (Reminyl) for Alzheimer's disease--will help the company achieve the increase in market share. Novartis will rely on oxcarbazepine (Trileptal) for epilepsy and rivastigmine (Exelon) for Alzheimer's disease to help drive its neurology portfolio; ironically, these are the same indications that are driving J&J."

About DR Pipeline Reports from Decision Resources

DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. Geared toward business development decision makers in the pharmaceutical, biotech, and financial industries, the DR Pipeline Reports expose major players in a therapeutic market and, more importantly, shed light on the emerging players that could significantly impact the current market once their pipelines are launched.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Depression Market Growth Will Finally Stall as SSRIs Lose Sales to Cheaper Generics

View Now